PMV PHARMACEUTICALS, INC. Operating Income
PMV PHARMACEUTICALS, INC. (PMVP) reported Operating Income of -$18.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$18.88M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$19.02M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$19.24M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$22.52M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was -$86.21M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was -$85.45M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$80.13M.
- PMV PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$77.04M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.88M 10-Q · filed 2026-08-14 | -$37.90M 10-Q · filed 2026-08-14 | -$57.14M derived: sum of 3 quarters · filed 2026-08-14 | -$79.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$19.02M 10-Q · filed 2026-05-12 | -$38.26M derived: sum of 2 quarters · filed 2026-05-12 | -$60.78M derived: sum of 3 quarters · filed 2026-05-12 | -$83.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$19.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$41.76M derived: sum of 2 quarters · filed 2026-03-06 | -$64.64M derived: sum of 3 quarters · filed 2026-08-14 | -$86.21M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$22.52M 10-Q · filed 2025-11-12 | -$45.40M derived: sum of 2 quarters · filed 2026-08-14 | -$66.96M 10-Q · filed 2025-11-12 | -$92.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$22.88M 10-Q · filed 2026-08-14 | -$44.44M 10-Q · filed 2026-08-14 | -$69.61M derived: sum of 3 quarters · filed 2026-08-14 | -$91.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$21.56M 10-Q · filed 2026-05-12 | -$46.73M derived: sum of 2 quarters · filed 2026-05-12 | -$68.62M derived: sum of 3 quarters · filed 2026-05-12 | -$88.79M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$25.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$47.06M derived: sum of 2 quarters · filed 2026-03-06 | -$67.23M derived: sum of 3 quarters · filed 2026-03-06 | -$85.45M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$21.89M 10-Q · filed 2025-11-12 | -$42.06M derived: sum of 2 quarters · filed 2025-11-12 | -$60.28M 10-Q · filed 2025-11-12 | -$79.18M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | -$20.17M 10-Q · filed 2025-08-07 | -$38.39M 10-Q · filed 2025-08-07 | -$57.29M derived: sum of 3 quarters · filed 2026-03-06 | -$76.92M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | -$18.22M 10-Q · filed 2025-05-09 | -$37.12M derived: sum of 2 quarters · filed 2026-03-06 | -$56.75M derived: sum of 3 quarters · filed 2026-03-06 | -$76.87M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | -$18.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$38.53M derived: sum of 2 quarters · filed 2026-03-06 | -$58.65M derived: sum of 3 quarters · filed 2026-03-06 | -$80.13M 10-K · filed 2026-03-06 |
| 2023-09-30 | -$19.63M 10-Q · filed 2024-11-07 | -$39.75M derived: sum of 2 quarters · filed 2024-11-07 | -$61.23M 10-Q · filed 2024-11-07 | -$82.39M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$20.12M 10-Q · filed 2024-08-08 | -$41.60M 10-Q · filed 2024-08-08 | -$62.76M derived: sum of 3 quarters · filed 2025-03-03 | -$82.14M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$21.48M 10-Q · filed 2024-05-09 | -$42.64M derived: sum of 2 quarters · filed 2025-03-03 | -$62.02M derived: sum of 3 quarters · filed 2025-03-03 | -$79.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$21.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$40.54M derived: sum of 2 quarters · filed 2025-03-03 | -$58.42M derived: sum of 3 quarters · filed 2025-03-03 | -$77.04M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$19.38M 10-Q · filed 2023-11-09 | -$37.26M derived: sum of 2 quarters · filed 2023-11-09 | -$55.88M 10-Q · filed 2023-11-09 | -$74.35M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$17.89M 10-Q · filed 2023-08-09 | -$36.50M 10-Q · filed 2023-08-09 | -$54.98M derived: sum of 3 quarters · filed 2024-02-29 | -$70.07M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$18.62M 10-Q · filed 2023-05-10 | -$37.09M derived: sum of 2 quarters · filed 2024-02-29 | -$52.19M derived: sum of 3 quarters · filed 2024-02-29 | -$65.24M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$18.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$33.57M derived: sum of 2 quarters · filed 2024-02-29 | -$46.62M derived: sum of 3 quarters · filed 2024-02-29 | -$58.29M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$15.10M 10-Q · filed 2022-11-08 | -$28.15M derived: sum of 2 quarters · filed 2022-11-08 | -$39.82M 10-Q · filed 2022-11-08 | -$50.32M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$13.05M 10-Q · filed 2022-08-09 | -$24.72M 10-Q · filed 2022-08-09 | -$35.23M derived: sum of 3 quarters · filed 2023-03-01 | -$43.93M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$11.67M 10-Q · filed 2022-05-10 | -$22.18M derived: sum of 2 quarters · filed 2023-03-01 | -$30.88M derived: sum of 3 quarters · filed 2023-03-01 | -$38.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$19.20M derived: sum of 2 quarters · filed 2023-03-01 | -$27.29M derived: sum of 3 quarters · filed 2023-03-01 | -$34.94M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$8.70M 10-Q · filed 2021-11-12 | -$16.79M derived: sum of 2 quarters · filed 2021-11-12 | -$24.44M 10-Q · filed 2021-11-12 | -$31.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$8.09M 10-Q · filed 2021-08-13 | -$15.74M 10-Q · filed 2021-08-13 | -$23.09M derived: sum of 3 quarters · filed 2022-03-01 | -$29.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$7.65M 10-Q · filed 2021-05-14 | -$15.01M derived: sum of 2 quarters · filed 2022-03-01 | -$21.45M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$13.79M derived: sum of 2 quarters · filed 2022-03-01 | -$26.64M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$6.44M 10-Q · filed 2020-11-13 | -$19.28M 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | -$18.89M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |